ERBB2 and sarcoma: As the first step in this direction, we performed a preclinical analysis of the cells in in vitro models of aRMS; our experiments demonstrated the potential of NK-92/5.28.z cells as adoptive immunotherapy for ERBB2-positive aRMS, justifying the further evaluation of this approach for the treatment of high-risk sarcomas in subsequent in vivo analyses as a prerequisite for a possible future phase I/II clinical trial.